Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant in acute migraine (ACHIEVE I)
NCT02828020Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ubrogepant in migraine (3 arms), sponsored by Allergan. Primary endpoints: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose and Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose. Started Jul 2016; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02828020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828020.